Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Manufacturer

Ascend Laboratories, LLC

105 drugs, 270 product strengths, 51 recalls on record.

Drugs Ascend Laboratories, LLC makes

Atorvastatin+2.4%Generic · 50 makersPharmacies pay from$0.699 open recallsAmlodipine-2.6%Generic · 33 makersPharmacies pay from$0.3017 open recallsGabapentin+4.5%Generic · 72 makersPharmacies pay from$0.667 open recallsRosuvastatin-1.4%Generic · 35 makersPharmacies pay from$0.954 open recallsVenlafaxine+0.3%Generic · 49 makersPharmacies pay from$2.14Clopidogrel-0.6%Generic · 33 makersPharmacies pay from$1.411 open recallMethylphenidate-1.0%Generic · 28 makersPharmacies pay from$3.65Unavailable1 open recallQuetiapine+3.8%Generic · 37 makersPharmacies pay from$0.63Pregabalin+5.4%Generic · 38 makersPharmacies pay from$1.341 open recallAripiprazole+6.2%Generic · 42 makersPharmacies pay from$3.503 open recallsRivaroxaban-3.6%Generic · 17 makersPharmacies pay from$18.80Being discontinuedDapagliflozin+0.3%Generic · 18 makersPharmacies pay from$4.89Finasteride-0.3%Generic · 30 makersPharmacies pay from$1.312 open recallsEsomeprazole-3.4%Generic · 107 makersPharmacies pay from$3.844 open recallsSildenafil+2.3%Generic · 54 makersPharmacies pay from$1.572 open recallsVarenicline+12.1%Generic · 22 makersPharmacies pay from$8.611 open recallIbuprofen+1.5%Generic · 240 makersPharmacies pay from$1.019 open recallsMetformin+2.2%Generic · 65 makersPharmacies pay from$0.44Being discontinued21 open recallsMetoprolol+1.0%Generic · 65 makersPharmacies pay from$0.48Being discontinued9 open recallsTamsulosin-2.1%Generic · 38 makersPharmacies pay from$1.47Famotidine-2.3%Generic · 123 makersPharmacies pay from$0.612 open recallsDiclofenac-1.0%Generic · 150 makersPharmacies pay from$1.89Being discontinued4 open recallsDuloxetine-3.0%Generic · 32 makersPharmacies pay from$2.9844 open recallsTopiramate+1.5%Generic · 36 makersPharmacies pay from$0.82Tizanidine+2.2%Generic · 41 makersPharmacies pay from$0.972 open recallsValsartan-0.3%Generic · 26 makersPharmacies pay from$2.42Being discontinued54 open recallsCephalexin-2.7%Generic · 31 makersPharmacies pay from$2.708 open recallsLevetiracetam-1.9%Generic · 63 makersPharmacies pay from$1.702 open recallsOlmesartan+0.3%Generic · 21 makersPharmacies pay from$1.83Chlorthalidone-1.6%Generic · 31 makersPharmacies pay from$2.193 open recallsEzetimibe+5.6%Generic · 23 makersPharmacies pay from$2.11Nifedipine+0.4%Generic · 27 makersPharmacies pay from$3.28Oxcarbazepine+2.8%Generic · 35 makersPharmacies pay from$3.201 open recallLansoprazole+1.7%Generic · 57 makersPharmacies pay from$3.131 open recallRizatriptan-2.2%Generic · 14 makersPharmacies pay from$9.846 open recallsMesalamine-5.0%Generic · 33 makersPharmacies pay from$14.52Being discontinued1 open recallBenzonatate-6.1%Generic · 35 makersPharmacies pay from$1.851 open recallTriamcinolone-0.9%Generic · 70 makersPharmacies pay from$0.67In shortage15 open recallsMirabegron-2.6%Generic · 6 makersPharmacies pay from$1741 open recallTicagrelor-4.0%Generic · 21 makersPharmacies pay from$7.29Colchicine-2.6%Generic · 30 makersPharmacies pay from$3.57Sacubitril / valsartan-2.0%Generic · 19 makersPharmacies pay from$15.06Lidocaine-1.8%Generic · 396 makersPharmacies pay from$1.74Unavailable59 open recallsLacosamide+0.3%Generic · 48 makersPharmacies pay from$3.626 open recallsTobramycin-1.1%Generic · 42 makersPharmacies pay from$5.48Being discontinued6 open recallsMycophenolate mofetil-3.9%Generic · 33 makersPharmacies pay from$4.042 open recallsEnalapril+16.7%Generic · 29 makersPharmacies pay from$1.885 open recallsTacrolimus+4.1%Generic · 25 makersPharmacies pay from$3.583 open recallsVancomycinNo changeGeneric · 25 makersPharmacies pay from$23.05Being discontinued24 open recallsLurasidone+2.6%Generic · 22 makersPharmacies pay from$4.36Cefdinir-2.8%Generic · 24 makersPharmacies pay from$6.46Morphine+0.1%Generic · 17 makersPharmacies pay from$6.32Unavailable7 open recallsLinezolid+2.3%Generic · 23 makersPharmacies pay from$44.22Azelastine-2.4%Generic · 22 makersPharmacies pay from$5.842 open recallsFingolimod-9.9%Generic · 21 makersPharmacies pay from$42.681 open recallNebivolol+1.7%Generic · 18 makersPharmacies pay from$3.43Being discontinued2 open recallsTelmisartan+9.1%Generic · 20 makersPharmacies pay from$3.29Dexmethylphenidate+13.0%Generic · 12 makersPharmacies pay from$5.67Minocycline-2.3%Generic · 17 makersPharmacies pay from$5.481 open recallRabeprazole+4.1%Generic · 20 makersPharmacies pay from$6.99Ranolazine+0.9%Generic · 19 makersPharmacies pay from$4.993 open recallsTemazepam-1.5%Generic · 18 makersPharmacies pay from$2.19Sirolimus-1.4%Generic · 17 makersPharmacies pay from$21.381 open recallCefuroxime-2.0%Generic · 17 makersPharmacies pay from$8.221 open recallBrivaracetam-2.3%Generic · 13 makersPharmacies pay from$5.17Clobazam+5.3%Generic · 15 makersPharmacies pay from$7.313 open recallsMethadone+2.7%Generic · 16 makersPharmacies pay from$4.951 open recallAzathioprine+3.1%Generic · 15 makersPharmacies pay from$3.85Capecitabine-0.4%Generic · 16 makersPharmacies pay from$10.85Colesevelam+1.1%Generic · 15 makersPharmacies pay from$7.931 open recallCholestyramine resin+8.3%Generic · 14 makersPharmacies pay from$181Dabigatran etexilate+0.7%Generic · 13 makersPharmacies pay from$21.469 open recallsFamotidine / ibuprofen+3.2%Generic · 15 makersPharmacies pay from$22.091 open recallRoflumilast-2.8%Generic · 13 makersPharmacies pay from$9.07Cinacalcet+1.8%Generic · 13 makersPharmacies pay from$12.5720 open recallsDimethyl fumarate-3.0%Generic · 14 makersPharmacies pay from$11.45Hydrochlorothiazide / olmesartan-4.9%Generic · 13 makersPharmacies pay from$4.92Brompheniramine / dextromethorphan / pseudoephedrine+0.4%Generic · 14 makersPharmacies pay from$8.08Deferasirox-10.3%Generic · 13 makersPharmacies pay from$33.581 open recallMycophenolic acid-2.3%Generic · 12 makersPharmacies pay from$3.071 open recallSolifenacin-9.8%Generic · 13 makersPharmacies pay from$3.832 open recallsVigabatrinGeneric · 14 makersNo weekly priceBeing discontinuedItraconazole-6.8%Generic · 12 makersPharmacies pay from$25.46Being discontinuedRasagiline+7.6%Generic · 12 makersPharmacies pay from$13.80Rufinamide+4.4%Generic · 11 makersPharmacies pay from$27.721 open recallAmlodipine / olmesartan+7.5%Generic · 10 makersPharmacies pay from$7.054 open recallsChlordiazepoxide / clidinium+7.8%Generic · 12 makersPharmacies pay from$8.28Magnesium sulfate / potassium sulfate / sodium sulfate-1.6%Generic · 11 makersPharmacies pay from$31.39EverolimusNo changeGeneric · 8 makersPharmacies pay from$50.66Being discontinued5 open recallsEslicarbazepine+5.5%Generic · 8 makersPharmacies pay from$45.61Cefpodoxime+3.2%Generic · 9 makersPharmacies pay from$32.00Dapagliflozin / metformin+13.2%Generic · 7 makersPharmacies pay from$14.61Fosfomycin+0.6%Generic · 10 makersPharmacies pay from$26.372 open recallsTemozolomideNo changeGeneric · 9 makersPharmacies pay from$26.391 open recallDalfampridine-8.2%Generic · 9 makersPharmacies pay from$11.00Droxidopa-0.6%Generic · 8 makersPharmacies pay from$14.09Cefprozil-10.5%Generic · 7 makersPharmacies pay from$9.24Fesoterodine+5.4%Generic · 7 makersPharmacies pay from$23.302 open recallsSilver sulfadiazine+0.2%Generic · 8 makersPharmacies pay from$13.01Ezetimibe / simvastatin-3.3%Generic · 5 makersPharmacies pay from$5.541 open recallCefixime+1.8%Generic · 6 makersPharmacies pay from$122Lanthanum carbonate-1.9%Generic · 6 makersPharmacies pay from$93.444 open recallsTolvaptan-19.2%Generic · 6 makersPharmacies pay from$353Dronabinol-2.6%Generic · 5 makersPharmacies pay from$98.01Riluzole-0.7%Generic · 5 makersPharmacies pay from$8.74Unavailable

Recalls

Class IIOngoingOct 28, 2026Amlodipine and Olmesartan Medoxomil TabletsOut of specification due to dissolution.Ascend Laboratories, LLC · D-0045-2027Class IIIOngoingAug 5, 2026Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month...Ascend Laboratories, LLC · D-0737-2026Class IIIOngoingAug 5, 2026Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month...Ascend Laboratories, LLC · D-0738-2026Class IIIOngoingAug 5, 2026Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month...Ascend Laboratories, LLC · D-0739-2026Class IIOngoingJul 29, 2026Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications; Olmesartan Medoxomil content below specificationsAscend Laboratories, LLC · D-0712-2026Class IIIOngoingJul 29, 2026Dabigatran etexilate CapsulesFailed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total...Ascend Laboratories, LLC · D-0735-2026Class IIIOngoingJul 29, 2026Dabigatran etexilate CapsulesFailed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total...Ascend Laboratories, LLC · D-0736-2026Class IIOngoingJun 17, 2026Minocycline Hydrochloride Extended-Release TabletsFailed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysisAscend Laboratories, LLC · D-0597-2026Class IIOngoingJun 10, 2026Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications: Olmesartan Medoxomil content below specificationsAscend Laboratories, LLC · D-0556-2026Class IIOngoingMay 20, 2026Ascend LaboratoriesFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0547-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0017-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0018-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0019-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0020-2026Class IIOngoingSep 24, 2025Aripiprazole TabletsSuperpotent drugAscend Laboratories, LLC · D-0645-2025Class IIOngoingAug 20, 2025Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications: low dissolution resultsAscend Laboratories, LLC · D-0576-2025Class IIOngoingJul 23, 2025Rizatriptan Benzoate TabletsCGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.Ascend Laboratories, LLC · D-0533-2025Class IIOngoingJul 23, 2025Rizatriptan Benzoate TabletsCGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.Ascend Laboratories, LLC · D-0534-2025Class IIOngoingJun 18, 2025Cephalexin for Oral SuspensionFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The...Ascend Laboratories, LLC · D-0468-2025Class IIOngoingJun 18, 2025Cephalexin for Oral SuspensionFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The...Ascend Laboratories, LLC · D-0469-2025Class IIOngoingDec 18, 2024Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limitAscend Laboratories, LLC · D-0129-2025Class IIOngoingDec 18, 2024Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limitAscend Laboratories, LLC · D-0130-2025Class IIOngoingOct 2, 2024Mycophenolic Acid Delayed-Release Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0668-2024Class IIOngoingFeb 28, 2024Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation Specification: Out of specification for organic impuritiesAscend Laboratories, LLC · D-0339-2024Class IIOngoingJan 24, 2024Ibuprofen and Famotidine Tablets 800mg/26.6mgPresence of Foreign Tablet/Capsule: A stray Rasagiline Mesylate 1 mg tablet was discovered in an unopened bottle of Ibuprofen and Famotidine.Ascend Laboratories, LLC · D-0237-2024Class IIITerminatedSep 13, 2023Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation Specifications: Out-of-specification results observed for the organic impurities test at 6 months, RT Stability.Ascend Laboratories, LLC · D-1145-2023Class IIOngoingJul 26, 2023Fingolimod CapsulesFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0925-2023Class IIOngoingApr 26, 2023Aripiprazole TabletsOut of specification (OOS) for Spectroscopic Identification test by IR.Ascend Laboratories, LLC · D-0539-2023Class IIOngoingApr 5, 2023Dabigatran Etexilate 150mg CapsulesCGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.Ascend Laboratories, LLC · D-0534-2023Class IIOngoingApr 5, 2023Dabigatran Etexilate CapsulesCGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.Ascend Laboratories, LLC · D-0533-2023

About Ascend Laboratories, LLC

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.